{"id":"66d85ea1937e","type":"article","url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","title":"5-jaarsfollow-up van intracoronaire celtherapie na MI: REGENERATE-AMI","title_en":"Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13786","source_url":"https://doi.org/10.1002/ehf2.13786","authors":["Anthony Mathur","Doo Sun Sim","Fizzah Choudry","Jessry Veerapen","Martina Colicchia","Tymoteusz Turlejski","Mohsin Hussain","Stephen Hamshere","Didier Locca","Roby Rakhit","Tom Crake","Jens Kastrup","Samir Agrawal","Daniel A Jones","John Martin"],"significance":5,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"The 5-year REGENERATE-AMI follow-up showed no sustained improvement in cardiac function from intracoronary autologous bone marrow cell therapy after acute MI, adding to the long-term negative evidence for post-infarction stem cell treatment.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"REGENERATE-AMI 5-jaarsfollow-up van intracoronaire autologe celtherapie na acuut MI.","abstract_original":"AIMS: The long-term outcomes of the intracoronary delivery of autologous bone marrow-derived cells (BMCs) after acute myocardial infarction are not well established. Following the promising 1 year results of the REGENERATE-AMI trial (despite it not achieving its primary endpoint), this paper presents the analysis of the 5 year clinical outcomes of these acute myocardial infarction patients who were treated with an early intracoronary autologous BMC infusion or placebo. METHODS AND RESULTS: A 5 year follow-up of major adverse cardiac events (defined as the composite of all-cause death, recurrent myocardial infarction, and all coronary revascularization) and of rehospitalization for heart failure was completed in 85 patients (BMC n = 46 and placebo n = 39). The incidence of major adverse cardiac events was similar between the BMC-treated patients and the placebo group (26.1% vs. 18.0%, P = 0.41). There were no cases of cardiac death in either group, but an increase in non-cardiac death was seen in the BMC group (6.5% vs. 0%, P = 0.11). The rates of recurrent myocardial infarction and repeat revascularization were similar between the two groups. There were no cases of rehospitalization for heart failure in either group. CONCLUSION: This 5 year follow-up analysis of the REGENERATE-AMI trial did not show an improvement in clinical outcomes for patients treated with cell therapy. This contrasts with the 1 year results which showed improvements in the surrogate outcome measures of ejection fraction and myocardial salvage index."}